

Humanigen, Inc.

08:50 16 Jun 2020

Humanigen says lenzilumab drug delivers better recovery time for coronavirus-associated pneumonia in cross-trial analysis

Humanigen Inc (OTCQB:HGEN) presented findings Tuesday showing that a cohort of 12 patients with coronavirus-associated pneumonia treated with its drug lenzilumab had a mean recovery time nearly twice as fast as a group treated with remdesivir in a separate trial.

In a recent Mayo Clinic study, a group treated with lenzilumab showed a median recovery time of five days and a 100% survival rate at the data cut-off point. By comparison, a group of patients with similar baseline characteristics treated with Gilead Sciences' remdesivir had a median recovery time of 10 to 11 days.

Remdesivir was previously granted Emergency Use Authorization by the US Food and Drug Administration.

READ: Humanigen sees 12 patients with coronavirus pneumonia recover after lenzilumab treatment in Mayo Clinic study

The data breaks down as follows:

Patient Baseline Characteristics; Days of Treatment	1 day Lenzilumab	5 day Remdesivir	10 day Remdesivir
Median age (IQR)	65 (52-70)	61 (50-69)	62 (50-71)
Male (%)	67%	60%	68%
Race (%)			
White	75%	71%	70%
Black	0%	10%	12%
Asian	17%	10%	13%
Other	8%	8%	5%
Median BMI (IQR)	29 (24-36)	29 (25-34)	29 (25-33)
Comorbidities			
Diabetes	58%	24%	22%
Hypertension	58%	50%	50%
Asthma	8%	14%	11%
Oxygenation Status			
IMV	-	2%	5%
High-Flow or NIPPV	33%	24%	30%
Low-Flow	67%	56%	54%
Ambient Air	0%	17%	11%
Median days of hospitalization before first dose (IQR)	2 (1-4)	2 (1-3)	2 (1-3)
Clinical Outcome Measures			
Median Time to Improvement	5	10	11
Median Time to Recovery	5	10	11
Clinical Improvement Day 14	100%	64%	54%

The company said it plans to hold a conference call to discuss the analysis at 4.30pm ET on Tuesday. Investors can dial (833) 714-0938 in the US or +1 (778) 560-2680 internationally. The conference ID number is 4442099.

1 Year Share Price Graph



February 2020 June 2020 September 20

Share Information

Code: HGEN
Listing: OTCQB
Sector: Pharma & Biotech
Website: www.humanigen.com

Company Synopsis:

Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies.

action@proactiveinvestors.com

Lenzilumab is designed to treat the cytokine storm, an overactive immune system response that can cause fever and inflammation and potentially lead to organ failure.

The Mayo Clinic study of lenzilumab was published in an article titled, "First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia."

All 12 patients were hospitalized at the Mayo Clinic and had severe or critical pneumonia as a result of the coronavirus. The patients required oxygen supplementation and had elevation in at least one inflammatory biomarker prior to receiving lenzilumab. The median age was 65 years old.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).